INDV
NASDAQIndivior Pharmaceuticals Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$37.60+5.45 (+16.95%)
2026-03-042026-06-05
News · 26 weeks90-94%
2025-12-142026-06-07
Mix3490d
- Other13(38%)
- Insider11(32%)
- SEC Filings8(24%)
- Earnings2(6%)
Latest news
25 items- PRNew Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare UtilizationCompared to patients adherent to monthly injectable buprenorphine, patients on other MOUD (adherent and non-adherent) were 3.5 to 8.1x more likely to return to opioid use.In a separate study, patients receiving monthly injectable buprenorphine had a 62% lower incidence of bacteremia and fewer inpatient, emergency, and outpatient visits than those receiving daily oral buprenorphine RICHMOND, Va., May 20, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc., (NASDAQ:INDV) today announced findings from two new real-world evidence studies showing that adherence to extended-release buprenorphine, a monthly injectable commercially available as SUBLOCADE®, is associated with lower relapse r
- SECIndivior Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders8-K - Indivior Pharmaceuticals, Inc. (0001625297) (Filer)
- INSIDERDirector Thompson Juliet covered exercise/tax liability with 1,117 shares and was granted 6,518 shares, increasing direct ownership by 71% to 12,973 units (SEC Form 4) (withholding tax)4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
- INSIDERDirector Humphreys Keith was granted 6,518 shares, increasing direct ownership by 68% to 16,042 units (SEC Form 4)4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
- INSIDERDirector Kingsley Stuart A was granted 6,518 shares, increasing direct ownership by 117% to 12,100 units (SEC Form 4)4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
- INSIDERDirector Ninivaggi Daniel A was granted 6,518 shares, increasing direct ownership by 32% to 27,163 units (SEC Form 4)4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
- INSIDERDirector Ryan Barbara was granted 6,518 shares, increasing direct ownership by 114% to 12,242 units (SEC Form 4)4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
- INSIDERDirector Stejbach Mark was granted 6,518 shares, increasing direct ownership by 32% to 27,087 units (SEC Form 4)4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
- INSIDERDirector Wheadon David E. was granted 10,430 shares, increasing direct ownership by 51% to 30,780 units (SEC Form 4)4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
- PRIndivior to Participate in Upcoming Investor ConferencesRICHMOND, Va., May 14, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) today announced that it will participate in the following upcoming investor conferences: 2026 Jefferies Global Healthcare Conference – New York, NY – June 3rd Joe Ciaffoni, Chief Executive Officer, and Ryan Preblick, Chief Financial Officer, will host 1x1 / group meetings on Wednesday, June 3rd and will also participate in a fireside chat on Wednesday, June 3rd at 11:05 a.m. U.S. EDT. Interested investors should contact their Jefferies representative to schedule a meeting. The fireside chat will be publicly available and can be accessed using the following weblink: Jefferies Webcast Link. Gol
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Indivior Pharmaceuticals Inc.SCHEDULE 13G/A - Indivior Pharmaceuticals, Inc. (0001625297) (Subject)
- SECIndivior Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Indivior Pharmaceuticals, Inc. (0001625297) (Filer)
- PRIndivior Announces $175 Million Accelerated Share RepurchaseRICHMOND, Va., May 04, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV), today announced that it has entered into a $175 million accelerated share repurchase agreement ("the ASR") with Barclays Bank PLC ("Barclays"). The ASR will be executed under Indivior's existing $400 million share repurchase program previously authorized by the Company's Board of Directors. The ASR reflects the Company's confidence in its long-term strategy, cash flow generation, and commitment to disciplined capital allocation. Under the ASR agreement, Indivior will make an upfront payment of $175 million to Barclays and expects to receive an initial delivery of 3,717,473 shares promptly followi
- SECSEC Form 10-Q filed by Indivior Pharmaceuticals Inc.10-Q - Indivior Pharmaceuticals, Inc. (0001625297) (Filer)
- SECSEC Form 8-K filed by Indivior Pharmaceuticals Inc.8-K - Indivior Pharmaceuticals, Inc. (0001625297) (Filer)
- PRIndivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 GuidanceQ1'26 Total Net Revenue of $317 Million, Up 19% YoYQ1'26 Total SUBLOCADE® Net Revenue of $232 Million, Up 32% YoY Q1'26 GAAP Net Income of $89 Million and Q1'26 Non-GAAP Net Income of $123 MillionRecord Quarterly Adjusted EBITDA of $164 Million in Q1'26, Up 112% YoYRepurchased Approximately Four Million Shares in Q1'26 for $125 MillionConference Call at 8:00 A.M. EDT Today RICHMOND, Va., April 30, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) today reported its financial results for the first quarter ended March 31, 2026, and raised its full-year 2026 financial guidance. "We are encouraged by our first quarter results, which reflect the progress we are making agai
- SECSEC Form SCHEDULE 13G filed by Indivior Pharmaceuticals Inc.SCHEDULE 13G - Indivior Pharmaceuticals, Inc. (0001625297) (Subject)
- PRIndivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use DisorderA collaboration with Virginia Tech supports recognizing remission as a treatment outcome—capturing symptoms, quality of life, and functional outcomes—beyond abstinence aloneOf all MOUD, monthly extended-release buprenorphine (BUP-XR) accounted for the smallest proportion of non-fatal and fatal OD events compared to no treatment. RICHMOND, Va., April 24, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV), a leader in the treatment of opioid use disorder (OUD), will present one new scientific poster and collaborated with VA Tech on a second poster which will be presented at the American Society of Addiction Medicine (ASAM) Annual Conference, held April 23-26, 2026, in San
- PRSurvey of Correctional Facility Staff: Monthly Opioid Treatment Shot May Help Reduce Medication MisuseRICHMOND, Va., April 16, 2026 (GLOBE NEWSWIRE) -- Indivior PLC (NASDAQ:INDV) today announced results from a national survey published in the Journal of Correctional Health Care showing that correctional leaders identify staffing and coordination gaps as key barriers to reducing diversion of medications for opioid use disorder (MOUD) and recognized long-acting injectable (LAI) buprenorphine as a strategy to help mitigate diversion and improve treatment in jail and prison settings. The cross-sectional survey included responses from 180 correctional professionals across U.S. jail and prison facilities. Among respondents, a strong majority — 88% of those working in jails and 87% in prisons —
- PRIndivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30thRICHMOND, Va., April 09, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) today announced that it will report its first quarter 2026 financial results on Thursday, April 30, 2026, at 7:00 a.m. U.S. EDT. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 8:00 a.m. U.S. EDT. Access to the Live Webcast Presentation: The webcast event and materials can be accessed on the "Investors" section of the company's website at www.indivior.com before the event begins. Live webcast link: https://edge.media-server.com/mmc/p/3k7nbxjp Participants may acc
- PRNew Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional FacilitiesModel estimates SUBLOCADE® may reduce staff time and associated costs compared with other medications for opioid use disorder in jails and prisons RICHMOND, Va., March 31, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc., (NASDAQ:INDV) today announced findings from a new cost impact model published in The Journal of Current Medical Research and Opinion, estimating that the use of extended-release buprenorphine, a monthly injectable commercially available as SUBLOCADE®, may reduce staff time and associated costs in jails and prisons compared with other medications for opioid use disorder (MOUD). "Correctional facilities face ongoing staffing constraints as the need for MOUD conti
- SECSEC Form DEFA14A filed by Indivior Pharmaceuticals Inc.DEFA14A - Indivior Pharmaceuticals, Inc. (0001625297) (Filer)
- SECSEC Form DEF 14A filed by Indivior Pharmaceuticals Inc.DEF 14A - Indivior Pharmaceuticals, Inc. (0001625297) (Filer)
- SECSEC Form SCHEDULE 13G filed by Indivior Pharmaceuticals Inc.SCHEDULE 13G - Indivior Pharmaceuticals, Inc. (0001625297) (Subject)
- INSIDERChief Financial Officer Preblick Ryan converted options into 6,302 shares and covered exercise/tax liability with 2,843 shares, increasing direct ownership by 1% to 320,751 units (SEC Form 4)4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
INDV FAQ
5 questionsWhere does INDV stock trade?
Indivior Pharmaceuticals Inc. (INDV) is listed on NASDAQ.What sector and industry is INDV in?
Indivior Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about INDV?
Indivior Pharmaceuticals Inc. has had 6 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $2700.00 price target on 2025-08-06. Recent price targets range from $1600.00 to $3700.00.What companies are similar to INDV?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare INDV side-by-side with any of them on Quantisnow.How can I track INDV on Quantisnow?
Quantisnow aggregates Indivior Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow INDV to receive live email and push alerts on every new disclosure.